Department of Oncology, Skåne University Hospital, Lund, Sweden; Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden.
Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden.
Clin Oncol (R Coll Radiol). 2021 Feb;33(2):92-97. doi: 10.1016/j.clon.2020.10.020. Epub 2020 Nov 12.
Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we summarise some of the most promising strategies identified so far.
肽受体放射性核素治疗是一种分子放疗，已在神经内分泌肿瘤患者的治疗中使用了二十多年。然而，直到最近才获得监管部门的批准。目前批准的治疗方案是一刀切的方案，即所有患者接受固定放射性药物（Lu-DOTATATE）的活性和固定数量的治疗周期。世界各地的几个研究小组研究了进一步改善肽受体放射性核素治疗结果的不同方法，多年来发表了许多有前途的回顾性和前瞻性临床研究。在这篇综述中，我们总结了迄今为止确定的一些最有前途的策略。
